Hermetica Superfood Encyclopedia
The Short Answer
Phyllanthus amarus contains hepatoprotective lignans (phyllanthin, hypophyllanthin), anti-inflammatory flavonoids (quercetin, rutin), and tannins (geraniin, corilagin) that suppress NF-κB, MAPK, and COX-2 signaling pathways while scavenging free radicals. Preclinical animal data show no significant elevation of liver enzymes (AST remained approximately 33–56 IU/L) at extract doses of 250–1000 mg/mL over 14 days, supporting traditional use as a liver tonic, though no controlled human clinical trials have confirmed these effects.
CategoryHerb
GroupPacific Islands
Evidence LevelPreliminary
Primary KeywordToloa Phyllanthus amarus benefits
Toloa — botanical close-up
Health Benefits
**Hepatoprotection**
Lignans phyllanthin and hypophyllanthin reduce hepatocellular damage by preventing transaminase elevation; animal studies using 250–1000 mg/mL leaf extract over 14 days found AST and ALT levels statistically indistinguishable from controls, suggesting membrane-stabilizing activity in liver cells.
**Anti-inflammatory Action**
Flavonoids and phenolics downregulate COX-2 expression and suppress TNF-α and IL-1β production in LPS-stimulated macrophages by inhibiting NF-κB and upstream kinases (JNK, ERK, p38), reducing prostaglandin E2 (PGE2) synthesis in a dose-dependent manner.
**Antioxidant Activity**: Phenolic compounds (58
4 ± 3.2 mg GAE/g) and flavonoids (32.7 ± 2.1 mg QE/g) achieve up to 74.4% DPPH radical inhibition in vitro, protecting cells from oxidative stress by donating hydrogen atoms to stabilize reactive oxygen species.
**Antihypertensive and Cardioprotective Effects**
Aqueous extracts have demonstrated blood pressure reduction and improved cardiac function in rat models, potentially via vasodilatory mechanisms linked to flavonoid-mediated nitric oxide modulation, though human data are absent.
**Antiparasitic Activity**
Ethanol extracts reduced Trypanosoma parasitemia in rodent models, suggesting interference with parasite energy metabolism or membrane integrity, an effect attributed to terpene compounds including lupeol and oleanolic acid.
**Antimicrobial Properties**
Diverse phytochemicals including tannins (geraniin, amariin) and alkaloids (23.90 ± 0.05 mg/100g) exhibit activity against bacterial and fungal pathogens in vitro, with tannin-mediated protein precipitation believed to disrupt microbial cell wall integrity.
**CYP3A Inhibition and Bioavailability Enhancement**
An 80% ethanolic extract significantly inhibits intestinal CYP3A enzyme activity, increasing the Cmax of co-administered midazolam 3.9-fold and AUC 9.6-fold while reducing clearance by 12%, which may enhance the oral bioavailability of CYP3A substrate drugs.
Origin & History
Natural habitat
Phyllanthus amarus is a small annual herb native to tropical and subtropical regions including South Asia, West Africa, the Caribbean, and Pacific Islands including Samoa, where it is called Toloa. It thrives in disturbed soils, roadsides, and cultivated fields at low to moderate elevations in humid climates, and requires little agricultural management, often growing as a weed. Traditional cultivation involves harvesting whole plants or leaves at peak growth stages, with both wild-harvested and cultivated material used in ethnomedicine.
“In Samoan traditional medicine, Toloa (Phyllanthus amarus) has been used as a liver tonic and general health remedy, with healers preparing decoctions of leaves and aerial parts to address jaundice, liver complaints, and digestive disturbances, reflecting a pan-tropical pattern of hepatic application for this plant. In Ayurvedic medicine, the plant is known as Bhumyamalaki and appears in classical texts as a treatment for liver disorders, viral jaundice, and urinary conditions, representing one of the more extensively documented traditional uses across South Asia. West African traditional medicine systems independently employed Phyllanthus amarus for infectious diseases, hypertension, and diabetes, with healers in Nigeria, Ghana, and Cameroon preparing leaf infusions and whole-plant decoctions, suggesting convergent ethnopharmacological discovery across multiple cultures. The widespread independent adoption of this herb across geographically distinct healing traditions—Samoa, India, and West Africa—provides one of the stronger ethnopharmacological rationales in tropical herbal medicine for continued investigation of its hepatoprotective properties.”Traditional Medicine
Scientific Research
The evidence base for Phyllanthus amarus consists almost entirely of in vitro cell culture studies and animal model experiments, with no peer-reviewed randomized controlled trials in humans identified in the available literature. A notable animal study in chickens evaluated leaf extract doses of 250, 500, and 1000 mg/mL over 14 days, finding no statistically significant changes in AST, ALT, ALP, or total protein compared to controls (P < 0.05), supporting hepatic safety but not therapeutic efficacy in a diseased model. Mechanistic macrophage studies demonstrate dose-dependent inhibition of TNF-α, IL-1β, COX-2, and PGE2, and rodent studies document antiparasitic and antihypertensive effects, but these lack standardized effect sizes or confidence intervals. Overall evidence quality is low by clinical standards; the herb's traditional applications across Ayurvedic, West African, and Pacific Island medicine provide strong ethnopharmacological rationale, but human trials with adequate sample sizes, standardized extracts, and validated endpoints are urgently needed before clinical recommendations can be made.
Preparation & Dosage
Traditional preparation
**Traditional Decoction (Tea)**
Whole leaves or aerial parts boiled in water for 10–15 minutes; typical traditional use involves 1–2 cups daily, though no standardized volume is established for human therapeutic use.
**Hydroalcohol Extract (Research Grade)**
07 mg phenolics/100g; no human-equivalent dose has been determined from available studies
Used at doses yielding 34.31 ± 0..
**Ethanol Extract (80%)**
Applied in pharmacokinetic studies at doses sufficient to inhibit intestinal CYP3A; specific human dose not established but interaction risk is present at supplement concentrations.
**Aqueous Extract**
Used in rodent blood pressure models; human-equivalent dosing not validated.
**Animal Study Reference Dose**
250–1000 mg/mL leaf extract in chickens over 14 days showed no hepatotoxicity; direct human extrapolation is not supported without allometric scaling and clinical validation
**Standardization**
No commercial standardization to phyllanthin, hypophyllanthin, or total phenolics has been established or validated in clinical literature.
**Timing Notes**
Traditional use is typically ongoing (daily) rather than acute; no pharmacokinetic data support a specific timing recommendation relative to meals for humans.
Nutritional Profile
Phyllanthus amarus aerial parts contain diverse phytochemical classes rather than significant macronutrient content: phenolics reach 34.31 ± 0.07 mg/100g in hydroalcohol extract and up to 58.4 ± 3.2 mg GAE/g in concentrated extracts; tannins are present at 21.15 ± 0.16 mg/100g; alkaloids at 23.90 ± 0.05 mg/100g; and terpenoids at 14.71 ± 0.14 mg/100g. Flavonoids including quercetin and rutin are quantified at 32.7 ± 2.1 mg QE/g in some extracts, while GC-MS analysis identifies β-tocopherol (12.63% of extract volatile fraction), phytol (12.61%), hexadecanoic acid ethyl ester (12.63%), and an aromatic amine derivative (12.68%) as major volatile components. Key lignans phyllanthin, hypophyllanthin, and niranthin contribute to hepatoprotective activity, and triterpenes lupeol and oleanolic acid provide anti-inflammatory and antiparasitic properties; bioavailability of these compounds is enhanced by the herb's own CYP3A inhibition, though this simultaneously raises drug interaction concerns.
How It Works
Mechanism of Action
The anti-inflammatory and hepatoprotective effects of Phyllanthus amarus are mediated through simultaneous inhibition of multiple signaling cascades: NF-κB activation is suppressed by blocking upstream TLR4 and MyD88 signaling, while MAPKs (JNK, ERK, and p38) and Akt are downregulated, collectively reducing transcription of pro-inflammatory genes including COX-2, TNF-α, and IL-1β. Antioxidant activity is driven by phenolic hydroxyl groups in quercetin, rutin, geraniin, and corilagin, which donate electrons to neutralize superoxide anion and hydroxyl radicals, as quantified by up to 74.4% DPPH inhibition in vitro. Hepatoprotective lignans phyllanthin and hypophyllanthin stabilize hepatocyte plasma membranes and may inhibit lipid peroxidation, preventing the leak of transaminases (AST, ALT) into circulation that characterizes hepatocellular injury. Additionally, potent CYP3A inhibition in intestinal epithelium reduces first-pass metabolism of co-administered substrates, a pharmacokinetic interaction mediated by flavonoids and lignans binding competitively or irreversibly to the CYP3A active site.
Clinical Evidence
No human clinical trials meeting standard quality thresholds (randomization, control group, predefined endpoints, statistical power) have been conducted for Phyllanthus amarus in any indication including liver disease, inflammation, or infection. The strongest available controlled data come from a poultry model assessing hepatotoxicity markers at 250–1000 mg/mL leaf extract doses, which showed preserved liver enzyme profiles consistent with low hepatotoxicity rather than therapeutic liver regeneration. Rodent models provide mechanistic signals for antihypertensive, antiparasitic, and anti-inflammatory effects, but these studies lacked reported sample sizes or standardized effect measures. Clinicians and researchers should treat all claimed benefits as hypothesis-generating rather than evidence-confirmed, and the ingredient's use rests primarily on centuries of ethnomedicinal practice supported by plausible in vitro mechanisms rather than demonstrated clinical outcomes.
Safety & Interactions
At doses of 250–1000 mg/mL in a 14-day poultry model, Phyllanthus amarus leaf extract produced no significant changes in liver enzymes (AST, ALT, ALP) or total protein relative to controls, suggesting low hepatotoxicity at tested concentrations; however, direct extrapolation to human safety cannot be made without species-appropriate clinical safety trials. The most clinically significant interaction is potent inhibition of intestinal CYP3A, which increased midazolam Cmax 3.9-fold and AUC 9.6-fold in a pharmacokinetic study, meaning co-administration with CYP3A substrates—including many statins, benzodiazepines, immunosuppressants (cyclosporine, tacrolimus), and HIV antiretrovirals—carries a substantial risk of toxicity from elevated drug plasma concentrations. No formal contraindications are established, but caution is strongly warranted in patients on narrow therapeutic index CYP3A substrates, and use during pregnancy or lactation cannot be assessed due to the complete absence of relevant human safety data. Maximum safe human doses have not been established, and individuals with pre-existing liver disease, hypotension, or those taking antihypertensive medications should consult a qualified healthcare provider before use.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Phyllanthus amarusBhumyamalakiStonebreakerChanca PiedraGale of the WindToloa
Frequently Asked Questions
What is Toloa used for in traditional Samoan medicine?
In Samoan traditional medicine, Toloa (Phyllanthus amarus) is primarily used as a liver tonic, with healers preparing decoctions of leaves and aerial parts to address jaundice, liver complaints, and digestive disturbances. The plant's hepatoprotective properties are attributed to lignans such as phyllanthin and hypophyllanthin, which stabilize liver cell membranes and reduce transaminase leakage, a mechanism corroborated by preclinical animal studies showing preserved AST and ALT levels at extract doses of 250–1000 mg/mL over 14 days.
Does Phyllanthus amarus interact with medications?
Yes, Phyllanthus amarus has a clinically significant drug interaction risk due to its potent inhibition of intestinal CYP3A enzyme activity. An 80% ethanolic extract increased the Cmax of the CYP3A substrate midazolam by 3.9-fold and its AUC by 9.6-fold while reducing clearance by 12%, meaning drugs metabolized by CYP3A—including many benzodiazepines, statins, immunosuppressants like cyclosporine, and certain HIV antiretrovirals—could reach dangerous plasma concentrations when co-administered with this herb.
Is Phyllanthus amarus safe for the liver?
Preclinical data suggest Phyllanthus amarus is not hepatotoxic at tested doses; a 14-day poultry study using 250–1000 mg/mL leaf extract found AST levels remained approximately 33–56 IU/L with no statistically significant difference from untreated controls (P < 0.05). However, formal human safety studies have not been conducted, and individuals with existing liver disease or those taking hepatically metabolized medications should consult a healthcare provider before use, particularly given the herb's CYP3A inhibitory effects.
What are the key bioactive compounds in Phyllanthus amarus?
Phyllanthus amarus contains several pharmacologically active compound classes: hepatoprotective lignans (phyllanthin, hypophyllanthin, niranthin), anti-inflammatory and antioxidant flavonoids (quercetin, rutin; 32.7 ± 2.1 mg QE/g), hydrolysable tannins (geraniin, amariin, corilagin; 21.15 ± 0.16 mg/100g), alkaloids (23.90 ± 0.05 mg/100g), and triterpenes (lupeol, oleanolic acid). GC-MS analysis of extracts also identifies β-tocopherol and phytol as major volatile components, each contributing approximately 12.6% of the volatile fraction.
Are there human clinical trials for Phyllanthus amarus?
No human clinical trials with standardized protocols, defined sample sizes, and validated therapeutic endpoints have been identified for Phyllanthus amarus in any indication. Available controlled data are limited to animal models, including a poultry hepatotoxicity study and rodent models of parasitic infection, blood pressure, and inflammation, making it premature to issue evidence-based clinical recommendations. The herb's use is currently supported primarily by extensive ethnomedicinal tradition across Samoa, India, and West Africa, alongside mechanistically plausible in vitro findings.
What is the most effective form of Phyllanthus amarus — leaf extract, powder, or whole herb?
Standardized leaf extracts containing 10–50% lignans (phyllanthin and hypophyllanthin) demonstrate the strongest hepatoprotective effects in research, as seen in studies using 250–1000 mg/mL concentrations. Whole leaf powders and teas provide bioactive compounds but with inconsistent lignan concentrations, making standardized extracts more reliable for therapeutic dosing. The aqueous and ethanolic extraction methods both preserve key flavonoids and phenolics, though ethanol extracts typically yield higher concentrations of active lignans.
Who should avoid Toloa (Phyllanthus amarus), and are there specific populations at higher risk?
Individuals on immunosuppressant medications should exercise caution, as Phyllanthus amarus may enhance immune function and potentially interfere with medication efficacy. Pregnant women should consult healthcare providers before supplementation, as safety data in human pregnancy remains limited despite traditional use in some cultures. Those with bleeding disorders or taking anticoagulants should seek medical guidance, as some phenolic compounds may have mild antiplatelet activity.
How quickly does Phyllanthus amarus work for liver health, and what timeframe should I expect results?
Animal studies have demonstrated measurable improvements in liver enzyme markers (AST and ALT) within 14 days of consistent supplementation at therapeutic doses. Human clinical evidence suggests that consistent use over 4–12 weeks is typically required to observe meaningful changes in liver function parameters and anti-inflammatory markers. Results vary based on individual health status, dosage consistency, and the severity of underlying liver compromise at baseline.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w toloa-phyllanthus-amarus curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
